DK1520175T3 - Oncolytiske vira som midler til fænotypebestemmelse af neoplasmer - Google Patents

Oncolytiske vira som midler til fænotypebestemmelse af neoplasmer

Info

Publication number
DK1520175T3
DK1520175T3 DK03737795T DK03737795T DK1520175T3 DK 1520175 T3 DK1520175 T3 DK 1520175T3 DK 03737795 T DK03737795 T DK 03737795T DK 03737795 T DK03737795 T DK 03737795T DK 1520175 T3 DK1520175 T3 DK 1520175T3
Authority
DK
Denmark
Prior art keywords
neoplasms
agents
oncolytic viruses
phenotype determination
phenotype
Prior art date
Application number
DK03737795T
Other languages
Danish (da)
English (en)
Inventor
Bradley G Thompson
Matthew C Coffey
Original Assignee
Oncolytics Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncolytics Biotech Inc filed Critical Oncolytics Biotech Inc
Application granted granted Critical
Publication of DK1520175T3 publication Critical patent/DK1520175T3/da

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5748—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving oncogenic proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/14—Reoviridae, e.g. rotavirus, bluetongue virus, Colorado tick fever virus
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/975—Kit

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DK03737795T 2002-06-28 2003-06-25 Oncolytiske vira som midler til fænotypebestemmelse af neoplasmer DK1520175T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US39203102P 2002-06-28 2002-06-28
US44318803P 2003-01-29 2003-01-29
PCT/CA2003/000951 WO2004003562A2 (en) 2002-06-28 2003-06-25 Oncolytic viruses as phenotyping agents for neoplasms

Publications (1)

Publication Number Publication Date
DK1520175T3 true DK1520175T3 (da) 2008-02-11

Family

ID=30003222

Family Applications (2)

Application Number Title Priority Date Filing Date
DK03737795T DK1520175T3 (da) 2002-06-28 2003-06-25 Oncolytiske vira som midler til fænotypebestemmelse af neoplasmer
DK07021569.4T DK1890151T3 (da) 2002-06-28 2003-06-25 Onkolytiske vira som midler til fænotypebestemmelse for neoplasmer

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK07021569.4T DK1890151T3 (da) 2002-06-28 2003-06-25 Onkolytiske vira som midler til fænotypebestemmelse for neoplasmer

Country Status (20)

Country Link
US (3) US7306902B2 (pt)
EP (2) EP1890151B1 (pt)
JP (1) JP2005531306A (pt)
CN (1) CN1666105B (pt)
AR (1) AR039768A1 (pt)
AT (2) ATE555388T1 (pt)
AU (2) AU2003245760B2 (pt)
BR (1) BR0311983A (pt)
CA (1) CA2487824C (pt)
DE (1) DE60317331T2 (pt)
DK (2) DK1520175T3 (pt)
ES (2) ES2385845T3 (pt)
HK (2) HK1069877A1 (pt)
IL (2) IL165498A0 (pt)
MX (1) MXPA04012414A (pt)
NZ (1) NZ537116A (pt)
PT (1) PT1890151E (pt)
SI (1) SI1890151T1 (pt)
TW (3) TWI327167B (pt)
WO (1) WO2004003562A2 (pt)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPQ425699A0 (en) 1999-11-25 1999-12-23 University Of Newcastle Research Associates Limited, The A method of treating a malignancy in a subject and a pharmaceutical composition for use in same
US8491884B2 (en) 2000-05-03 2013-07-23 Oncolytics Biotech Inc. Virus clearance of neoplastic cells from mixed cellular compositions
US7306902B2 (en) * 2002-06-28 2007-12-11 Oncolyties Biotech Inc. Oncolytic viruses as phenotyping agents for neoplasms
US20040115170A1 (en) * 2001-11-30 2004-06-17 Brown Earl Garnet Oncolytic virus
AU2003249059A1 (en) 2002-07-24 2004-02-09 Arizona Board Of Regents Use of vaccinia virus deleted for the e3l gene as a vaccine vector
AU2002953436A0 (en) 2002-12-18 2003-01-09 The University Of Newcastle Research Associates Limited A method of treating a malignancy in a subject via direct picornaviral-mediated oncolysis
US20070036758A1 (en) * 2003-07-08 2007-02-15 Bertram Jacobs Mutants of vaccinia virus as oncolytic agents
WO2005111200A1 (en) * 2004-05-17 2005-11-24 Universite De Montreal Novel strains of reoviruses and methods of uses thereof
US10260049B2 (en) 2005-08-01 2019-04-16 Virocure, Inc. Attenuated reovirus
US10668119B2 (en) 2005-08-01 2020-06-02 Virocure, Inc. Attenuated reovirus
EP1979000B1 (en) * 2005-12-22 2011-07-13 Memorial Sloan-Kettering Cancer Center Method for detection of cancer cells using virus
BRPI0707654A2 (pt) * 2006-02-13 2011-05-10 Oncolytics Biotech Inc mÉtodo para tratar ou melhorar um tumor sàlido em um indivÍduo
US10369171B2 (en) 2007-03-13 2019-08-06 Virocure, Inc. Attenuated reoviruses for selection of cell populations
WO2008144067A1 (en) * 2007-05-21 2008-11-27 Board Of Regents, University Of Texas System Methods and compositions for treatment of cancer using oncolytic rsv activity
KR101585702B1 (ko) * 2008-05-22 2016-01-15 제일약품주식회사 종양파괴 바이러스 요법에 대한 과다증식성 세포의 종양 억제인자-기초된 민감성
US8470312B2 (en) * 2008-05-27 2013-06-25 Oncolytics Biotech, Inc. Abrogating proinflammatory cytokine production during oncolytic reovirus therapy
EP2296678A4 (en) * 2008-05-27 2012-03-21 Oncolytics Biotech Inc MODULATION OF INTERSTITIAL PRESSURE AND ONCOLYTIC VIRUS RELIEF AND DISTRIBUTION
US8481297B2 (en) * 2009-01-08 2013-07-09 Yale University Compositions and methods of use of an oncolytic vesicular stomatitis virus
ES2385251B1 (es) 2009-05-06 2013-05-06 Fundació Privada Institut D'investigació Biomèdica De Bellvitge Adenovirus oncolíticos para el tratamiento del cáncer.
US9428565B2 (en) 2011-01-31 2016-08-30 The General Hospital Corporation Treatment and bioluminescent visualization using multimodal TRAIL molecules
US8859256B2 (en) 2011-10-05 2014-10-14 Genelux Corporation Method for detecting replication or colonization of a biological therapeutic
US20140087362A1 (en) 2012-03-16 2014-03-27 Aladar A. Szalay Methods for assessing effectiveness and monitoring oncolytic virus treatment
US20130280170A1 (en) 2012-04-20 2013-10-24 Aladar A. Szalay Imaging methods for oncolytic virus therapy
EP2877572B1 (en) 2012-07-24 2018-11-28 The General Hospital Corporation Oncolytic virus therapy for resistant tumors
WO2014035474A1 (en) 2012-08-30 2014-03-06 The General Hospital Corporation Compositions and methods for treating cancer
US20140140959A1 (en) 2012-10-05 2014-05-22 Aladar A. Szalay Energy Absorbing-Based Diagnostic and Therapeutic Methods Employing Nucleic Acid Molecules Encoding Chromophore-Producing Enzymes
US20160303174A1 (en) * 2013-12-11 2016-10-20 The General Hospital Corporation Stem cell delivered oncolytic herpes simplex virus and methods for treating brain tumors
US10238700B2 (en) 2014-01-02 2019-03-26 Genelux Corporation Oncolytic virus adjunct therapy with agents that increase virus infectivity
DK3207130T3 (da) 2014-10-14 2019-11-11 Halozyme Inc Sammensætninger af Adenosin Deaminase-2 (ADA2), varianter deraf og fremgangsmåder til anvendelse af samme
CN115300622A (zh) 2015-02-25 2022-11-08 纪念斯隆-凯特琳癌症中心 使用灭活的修饰的痘苗病毒安卡拉作为实体肿瘤的单一免疫疗法或与免疫检查点阻断剂组合
EP3283088A4 (en) 2015-04-17 2018-10-24 Memorial Sloan-Kettering Cancer Center Use of mva or mvadeltae3l as immunotherapeutic agents against solid tumors
CA3015650A1 (en) 2016-02-25 2017-08-31 Memorial Sloan Kettering Cancer Center Replication competent attenuated vaccinia viruses with deletion of thymidine kinase with and without the expression of human flt3l or gm-csf for cancer immunotherapy
JP7034080B2 (ja) 2016-02-25 2022-03-11 メモリアル スローン ケタリング キャンサー センター ヒトｆｌｔ３ｌを発現する組換えｍｖａまたはｍｖａδｅ３ｌおよび固形腫瘍に対する免疫療法薬としてのそれらの使用
JP7527758B2 (ja) 2016-04-15 2024-08-05 アルパイン イミューン サイエンシズ インコーポレイテッド Ｃｄ８０バリアント免疫調節タンパク質およびその使用
KR102536850B1 (ko) 2016-04-15 2023-05-26 알파인 이뮨 사이언시즈, 인코포레이티드 Icos 리간드 변이체 면역조절 단백질 및 그의 용도
WO2017205674A1 (en) 2016-05-25 2017-11-30 Arizona Board Of Regents On Behalf Of Arizona State University Oncolytic vaccinia virus mutants and using same for cancer treatment
CA3032120A1 (en) 2016-07-28 2018-02-01 Alpine Immune Sciences, Inc. Cd155 variant immunomodulatory proteins and uses thereof
US11834490B2 (en) 2016-07-28 2023-12-05 Alpine Immune Sciences, Inc. CD112 variant immunomodulatory proteins and uses thereof
US11471488B2 (en) 2016-07-28 2022-10-18 Alpine Immune Sciences, Inc. CD155 variant immunomodulatory proteins and uses thereof
CN117085047A (zh) * 2016-09-27 2023-11-21 萨特治疗学有限公司 优化的溶瘤病毒及其用途
JP2020500010A (ja) 2016-10-20 2020-01-09 アルパイン イミューン サイエンシズ インコーポレイテッド 分泌性バリアント免疫調節タンパク質および改変細胞療法
US11920156B2 (en) 2017-02-09 2024-03-05 Indapta Therapeutics, Inc. Engineered natural killer (NK) cells and compositions and methods thereof
US11732022B2 (en) 2017-03-16 2023-08-22 Alpine Immune Sciences, Inc. PD-L2 variant immunomodulatory proteins and uses thereof
EP4306537A3 (en) 2017-03-16 2024-03-06 Alpine Immune Sciences, Inc. Pd-l1 variant immunomodulatory proteins and uses thereof
EP3596114A2 (en) 2017-03-16 2020-01-22 Alpine Immune Sciences, Inc. Cd80 variant immunomodulatory proteins and uses thereof
WO2018209315A1 (en) 2017-05-12 2018-11-15 Memorial Sloan Kettering Cancer Center Vaccinia virus mutants useful for cancer immunotherapy
WO2019079520A2 (en) 2017-10-18 2019-04-25 Alpine Immune Sciences, Inc. ICOS VARIANT LIGAND IMMUNOMODULATORY IMMUNOMODULATORY PROTEINS, COMPOSITIONS AND METHODS THEREOF
WO2019236633A2 (en) 2018-06-04 2019-12-12 Calidi Biotherapeutics, Inc. Cell-based vehicles for potentiation of viral therapy
US11505782B2 (en) 2018-06-04 2022-11-22 Calidi Biotherapeutics, Inc. Cell-based vehicles for potentiation of viral therapy
US12065476B2 (en) 2018-06-15 2024-08-20 Alpine Immune Sciences, Inc. PD-1 variant immunomodulatory proteins and uses thereof
US11242528B2 (en) 2018-08-28 2022-02-08 Actym Therapeutics, Inc. Engineered immunostimulatory bacterial strains and uses thereof
JP7329593B2 (ja) 2018-11-06 2023-08-18 カリディ・バイオセラピューティクス・インコーポレイテッド 細胞媒介性腫瘍溶解性ウイルス治療のための増強された系
JP7541516B2 (ja) 2018-11-21 2024-08-28 インダプタ セラピューティクス インコーポレイテッド ナチュラルキラー（ｎｋ）細胞サブセットの増大のための方法ならびに関連する組成物および方法
CA3120868A1 (en) 2018-11-30 2020-06-04 Alpine Immune Sciences, Inc. Cd86 variant immunomodulatory proteins and uses thereof
US12024709B2 (en) 2019-02-27 2024-07-02 Actym Therapeutics, Inc. Immunostimulatory bacteria engineered to colonize tumors, tumor-resident immune cells, and the tumor microenvironment
SG11202108459QA (en) 2019-02-27 2021-09-29 Actym Therapeutics Inc Immunostimulatory bacteria engineered to colonize tumors, tumor-resident immune cells, and the tumor microenvironment
KR20230088306A (ko) 2020-04-22 2023-06-19 인답타 세라뷰틱스 인코포레이티드 자연 살해(ｎｋ) 세포 조성물 및 이를 생성하는 방법
WO2022147481A1 (en) 2020-12-30 2022-07-07 Ansun Biopharma Inc. Combination therapy of an oncolytic virus delivering a foreign antigen and an engineered immune cell expressing a chimeric receptor targeting the foreign antigen

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5747469A (en) * 1991-03-06 1998-05-05 Board Of Regents, The University Of Texas System Methods and compositions comprising DNA damaging agents and p53
US5670330A (en) * 1992-09-29 1997-09-23 Mcgill University Anti-tumor agent assay using PKR
US5846945A (en) 1993-02-16 1998-12-08 Onyx Pharmaceuticals, Inc. Cytopathic viruses for therapy and prophylaxis of neoplasia
CA2152941C (en) 1993-02-16 2003-04-22 Francis Mccormick Cytopathic viruses for therapy and prophylaxis of neoplasia
ATE236271T1 (de) 1993-04-30 2003-04-15 Wellstat Biologics Corp Verwendung der ndv zur herstellung eines medikaments zur krebsbehandlung
WO1995016464A1 (en) 1993-12-14 1995-06-22 Johns Hopkins University School Of Medicine Controlled release of pharmaceutically active substances for immunotherapy
WO1995032300A1 (en) 1994-05-23 1995-11-30 University Of Medicine & Dentistry Of New Jersey Selective biological destruction of tumor cells
US5585096A (en) 1994-06-23 1996-12-17 Georgetown University Replication-competent herpes simplex virus mediates destruction of neoplastic cells
US5840502A (en) 1994-08-31 1998-11-24 Activated Cell Therapy, Inc. Methods for enriching specific cell-types by density gradient centrifugation
US6777177B1 (en) * 1997-10-10 2004-08-17 Vanderbilt University Mammalian genes involved in viral infection and tumor suppression
US6136307A (en) * 1997-08-13 2000-10-24 Oncolytics Biotech Inc. Reovirus for the treatment of cellular proliferative disorders
CA2508238C (en) 1997-08-13 2008-01-15 Oncolytics Biotech Inc. Reovirus for the treatment of neoplasia
US6110461A (en) 1997-08-13 2000-08-29 Oncolytics Biotech Inc. Reovirus for the treatment of neoplasia
US7780962B2 (en) * 1997-10-09 2010-08-24 Wellstat Biologics Corporation Treatment of neoplasms with RNA viruses
HUP0003911A3 (en) 1997-10-09 2007-11-28 Pro Virus Treatment of neoplasms with viruses
US6475481B2 (en) 1997-11-18 2002-11-05 Canji Inc Purging of stem cell products
AU3001799A (en) 1998-03-12 1999-09-27 Trustees Of The University Of Pennsylvania, The Producer cells for replication selective viruses in the treatment of malignancy
US6528057B1 (en) 1998-08-31 2003-03-04 Julian L. Ambrus Method for removal of HIV and other viruses from blood
MXPA01010393A (es) 1999-04-15 2004-04-02 Pro Virus Inc Tratamiento de neoplasmas con virus.
DE19934788B4 (de) * 1999-07-27 2004-05-27 T-Mobile Deutschland Gmbh Verfahren zur automatischen Anpassung von Daten an die Fähigkeiten einer Nutzer-Software
CN1289098C (zh) 1999-09-17 2006-12-13 威尔斯塔生物公司 溶瘤病毒
CA2720361A1 (en) 1999-11-12 2001-05-25 Oncolytics Biotech, Inc. Viruses for the treatment of cellular proliferative disorders
AUPQ425699A0 (en) 1999-11-25 1999-12-23 University Of Newcastle Research Associates Limited, The A method of treating a malignancy in a subject and a pharmaceutical composition for use in same
AR028039A1 (es) 2000-05-03 2003-04-23 Oncolytics Biotech Inc Remocion de reovirus de celulas neoplasticas intermediadas por ras a partir de composiciones celulares mixtas
US7306902B2 (en) * 2002-06-28 2007-12-11 Oncolyties Biotech Inc. Oncolytic viruses as phenotyping agents for neoplasms
AR028040A1 (es) * 2000-05-03 2003-04-23 Oncolytics Biotech Inc Remocion de virus de celulas neoplasticas a partir de composiciones celulares mixtas
IL153570A0 (en) 2000-06-26 2003-07-06 Wellstat Biologics Corp Purging of cells using viruses
WO2002004596A2 (en) 2000-07-07 2002-01-17 President And Fellows Of Harvard College Diagnosing and treating cancer cells using mutant viruses
EP1332366B1 (en) 2000-11-09 2010-06-30 Oncolytics Biotech, Inc. Methods for the Assessment of Cellular Proliferative Disorders
US20030138405A1 (en) * 2001-04-17 2003-07-24 Juan Fueyo Conditionally replicative adenovirus to target the Rb and Rb-related pathways

Also Published As

Publication number Publication date
TW200940709A (en) 2009-10-01
MXPA04012414A (es) 2005-04-19
CN1666105A (zh) 2005-09-07
JP2005531306A (ja) 2005-10-20
US7306902B2 (en) 2007-12-11
BR0311983A (pt) 2005-04-26
AU2003245760A1 (en) 2004-01-19
CA2487824C (en) 2013-08-20
PT1890151E (pt) 2012-05-25
TWI402345B (zh) 2013-07-21
DE60317331D1 (de) 2007-12-20
EP1890151B1 (en) 2012-04-25
IL165498A0 (en) 2006-01-15
DE60317331T2 (de) 2008-08-21
ES2385845T3 (es) 2012-08-01
TW200401032A (en) 2004-01-16
HK1112509A1 (en) 2008-09-05
IL220139A (en) 2013-03-24
DK1890151T3 (da) 2012-06-18
AU2008207579A1 (en) 2008-09-18
WO2004003562A2 (en) 2004-01-08
ES2292981T3 (es) 2008-03-16
IL220139A0 (en) 2012-07-31
TWI334444B (en) 2010-12-11
AU2008207579B2 (en) 2011-10-20
AR039768A1 (es) 2005-03-09
US20100105122A1 (en) 2010-04-29
CA2487824A1 (en) 2004-01-08
TW201005097A (en) 2010-02-01
EP1520175B1 (en) 2007-11-07
US20080014577A1 (en) 2008-01-17
AU2003245760B2 (en) 2008-07-03
EP1520175A2 (en) 2005-04-06
SI1890151T1 (sl) 2012-08-31
TWI327167B (en) 2010-07-11
ATE555388T1 (de) 2012-05-15
HK1069877A1 (en) 2005-06-03
WO2004003562A3 (en) 2004-05-06
NZ537116A (en) 2008-04-30
ATE377754T1 (de) 2007-11-15
US20040029112A1 (en) 2004-02-12
US8222036B2 (en) 2012-07-17
EP1890151A1 (en) 2008-02-20
CN1666105B (zh) 2015-11-25

Similar Documents

Publication Publication Date Title
DK1520175T3 (da) Oncolytiske vira som midler til fænotypebestemmelse af neoplasmer
DK1423391T3 (da) Pyrrolopyrimidiner som midler til inhibering af cysteinproteaser
DK1730110T3 (da) Svovlforbindelser som inhibitorer af hepatitis C-virus NS3-serinprotease
NO20043642L (no) Heterocykiske tripeptider som hepatitt C inhibitorer
DK1575416T3 (da) Fremgangsmåder til diagnosticering af præeklampsi
IS8476A (is) Lifrarbólgu C-veirutálmar
IS8475A (is) Lifrarbólgu C-veirutálmar
DK3395339T3 (da) Hurtigt opløsende formulering af cinacalcet-hcl
IS7530A (is) Lifrarbólgu C-veirutálmar
DK1562589T3 (da) Diaminotriazoler der er nyttige som inhibitorer af proteinkinaser
DK1402075T3 (da) Udvikling af egnede mutationer til svækkelse af dengue-vira samt kimære dengue-vira
DK1492785T3 (da) 2-hydroxy-3-heteroarylindol-derivater som GSK3-inhibitorer
IS2761B (is) Ný amínóbensófenónefnasambönd
NO20023283D0 (no) Flammestopper
DK1802579T3 (da) Derivater af 3-arylaminopyridin
IS7607A (is) Ný útskipt indól
DK1504126T3 (da) Fremgangsmåde til regulering af genekspression
DK2060570T3 (da) Som modulatorer af dopamin-d3-receptorer anvendelige azabicyclo(3.1.0)hexanderivater
DK1737461T3 (da) Carbolin-derivater til inhibering af angiogenese
DK1542977T3 (da) 2,5-dioxoimidazolidin-4-ylacetamider og analoger som inhibitorer af metalloproteinase MMP12
DK1948176T3 (da) Diarylurinstoffer til behandling af pulmonær hypertension
DE602004025775D1 (de) Innengekühltes strömungsleitendes Komponent
DE602005019093D1 (de) Triazolsubstituierte aminobenzophenonverbindungen
DK1401828T3 (da) N-Formylhydroxylaminforbindelser som inhibitorer af PDF
ATE398450T1 (de) Derivate von aryl-chinazolin/aryl-2amino-phenyl- methanon zurförderung der freisetzung von parathormon